Biopsy Sciences, LLC had engaged in the development of breast biopsy site markers. The company offered HydroMARK, a biodegradable hydrogel polymer that included a central permanent metal marker that marks a breast biopsy site. The firm also developed and made available BioSEAL, a biopsy tract sealant that reduces the incidence of pneumothorax and chest tube placement following CT guided lung biopsy. The team were successfuly able to develop, patent, file for regulatory clearance and ultimately sell the VMark breast biopsy site marker, Maxi-Cell biopsy needle and the Bio-SEAL lung biopsy site sealant to Angiotech for $19 million in 2007. In May 2014, Biopsy Sciences then sold the othermajor par of the firm's asset portfolio - the HydroMARK breast cancer biopsy marker portfolio - to Devicor Medical Products Inc: effectively an acquisition of the firm.
